David Hough

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
    Schizophr Res 116:107-17. 2010
  2. pmc A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
    Danielle Coppola
    Janssen Research and Development, LLC, Raritan, New Jersey, USA
    BMC Psychiatry 12:26. 2012
  3. doi request reprint Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ, USA
    Prog Neuropsychopharmacol Biol Psychiatry 33:1022-31. 2009
  4. doi request reprint A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents
    Jaskaran Singh
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Biol Psychiatry 70:1179-87. 2011
  5. doi request reprint A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Gahan Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:218-26. 2011
  6. doi request reprint Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    J Clin Psychopharmacol 33:157-61. 2013
  7. doi request reprint Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study
    Joris Berwaerts
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ, USA
    J Affect Disord 136:e51-60. 2012
  8. pmc Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy
    Mahesh N Samtani
    Janssen Research and Development LLC, New Jersey, USA
    Br J Clin Pharmacol 82:1364-1370. 2016
  9. pmc A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey, USA
    Innov Clin Neurosci 8:26-33. 2011
  10. pmc Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia
    Danielle Coppola
    Dr Coppola, MD, Director, Neuroscience Therapeutic Area and, Ms Melkote, MSc, MPH, Manager, Biostatistics, Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, U S A Ms Lannie, M Sc, Scientist Clin Pharm, Johnson and Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica, NV, Beerse, Belgium Drs Singh, MD, Director, Neuroscience Therapeutic Area, Nuamah, PhD, Associate Director, Biostatistics, Gopal, MD, Senior Director Clinical Leader, Neuroscience Therapeutic Area, Hough, MD, Interim Manager Psychiatry Franchise, Neuroscience Therapeutic Area, Palumbo, MD, Department of Paediatrics
    Psychopharmacol Bull 44:54-72. 2011

Collaborators

Detail Information

Publications15

  1. doi request reprint Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
    Schizophr Res 116:107-17. 2010
    ..We assessed efficacy and tolerability of the injectable atypical antipsychotic paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia...
  2. pmc A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
    Danielle Coppola
    Janssen Research and Development, LLC, Raritan, New Jersey, USA
    BMC Psychiatry 12:26. 2012
    ..This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]) in stable patients with schizophrenia over a 1-year period...
  3. doi request reprint Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ, USA
    Prog Neuropsychopharmacol Biol Psychiatry 33:1022-31. 2009
    ..Paliperidone palmitate treatment was tolerated, irrespective of injection site, and thus could offer the choice of administration into either the deltoid or gluteal muscle to meet patient and physician preference...
  4. doi request reprint A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents
    Jaskaran Singh
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Biol Psychiatry 70:1179-87. 2011
    ..Paliperidone extended-release (ER) is approved for treatment of schizophrenia in adults but has not been evaluated in adolescents...
  5. doi request reprint A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Gahan Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:218-26. 2011
    ..4 [-1.62;2.38], per-protocol analysis set [primary analysis]). The tolerability and safety of PP was generally similar to RIS-LAI with no new safety or tolerability findings...
  6. doi request reprint Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    J Clin Psychopharmacol 33:157-61. 2013
    ..Apart from events described in existing product labeling, no new safety findings emerged...
  7. doi request reprint Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study
    Joris Berwaerts
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ, USA
    J Affect Disord 136:e51-60. 2012
    ..Atypical antipsychotics are effective in the treatment of bipolar I disorder. In this 3-week double-blind study, the efficacy and safety of paliperidone extended-release (ER) tablets were assessed in patients with acute mania...
  8. pmc Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy
    Mahesh N Samtani
    Janssen Research and Development LLC, New Jersey, USA
    Br J Clin Pharmacol 82:1364-1370. 2016
    ....
  9. pmc A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey, USA
    Innov Clin Neurosci 8:26-33. 2011
    ..First-month data of a 13-week acute schizophrenia study were used to compare paliperidone palmitate to oral risperidone during initiation of long-acting injectable risperidone...
  10. pmc Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia
    Danielle Coppola
    Dr Coppola, MD, Director, Neuroscience Therapeutic Area and, Ms Melkote, MSc, MPH, Manager, Biostatistics, Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, U S A Ms Lannie, M Sc, Scientist Clin Pharm, Johnson and Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica, NV, Beerse, Belgium Drs Singh, MD, Director, Neuroscience Therapeutic Area, Nuamah, PhD, Associate Director, Biostatistics, Gopal, MD, Senior Director Clinical Leader, Neuroscience Therapeutic Area, Hough, MD, Interim Manager Psychiatry Franchise, Neuroscience Therapeutic Area, Palumbo, MD, Department of Paediatrics
    Psychopharmacol Bull 44:54-72. 2011
    ..Paliperidone extended-release (paliperidone ER) is an approved oral antipsychotic medication (dosing range 3-12 mg/day) for treatment of schizophrenia and schizoaffective disorder in adults...
  11. doi request reprint Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
    Michelle Kramer
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ, USA
    Int J Neuropsychopharmacol 13:635-47. 2010
    ..PP (50 and 100 mg eq. doses) administered as a gluteal intramuscular injection was efficacious and generally tolerated in these patients with acute symptomatic schizophrenia...
  12. ncbi request reprint Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients
    Robert Howard
    Robert Howard, MD, MRCPsych, Division of Psychiatry, University College London, and Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King s College London Sergi G Costafreda, MD, PhD, Division of Psychiatry, University College London, London, UK Keith Karcher, MS, Danielle Coppola, MD, Janssen Research and Development, Jesse A Berlin, ScD, Johnson and Johnson, David Hough, MD, Janssen Research and Development, Titusville, New Jersey, USA
    Br J Psychiatry 209:378-384. 2016
    ..Use of antipsychotics to treat behavioural symptoms of dementia has been associated with increased risks of mortality and stroke. Little is known about individual patient characteristics that might be associated with bad or good outcomes...
  13. doi request reprint Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia
    Srihari Gopal
    a a Janssen Research and Development LLC, Raritan, NJ, USA
    Curr Med Res Opin 31:2043-54. 2015
    ..This commentary summarizes recommended dosing strategies for a recently developed 3 monthly long-acting injectable 1 (LAI) formulation of paliperidone palmitate (PP3M) for the treatment of schizophrenia in adults...
  14. doi request reprint Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study
    Justine M Kent
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, Titusville, NJ 08560, USA
    J Autism Dev Disord 43:1773-83. 2013
    ..Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. ..
  15. pmc Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    Neuropsychiatr Dis Treat 7:93-101. 2011
    ....